Have you been hospitalized for anti-GBM disease (Goodpasture disease)? You may be able to take part in a research study to help us learn if adding a drug to your treatment could help stop inflammation faster and help protect the kidneys.
People with kidney disease that have the APOL1 risk variant are at a greater risk for developing protein in their urine and chronic kidney disease. This research study is being done to determine if the investigational drug, VX-147 can slow or stop the worsening of kidney function as well as target the underlying cause of kidney disease.
Do you have severe sickle cell disease? If so, you may be eligible to participate in a research study that is looking at the safety and effectiveness of using your own modified stem cells as possible treatment.
Does your child have frequently relapsing or steroid dependent nephrotic syndrome? This study is testing a medicine called obinutuzumab, and comparing it with another one, mycophenolate mofetil (MMF), to see which works better for children with nephrotic syndrome.
Have you been infected with COVID-19? Are you a solid organ transplant recipient? Have you or your child received a COVID-19 vaccine or are planning to receive one? If so, you may be eligible to participate in a research study that will assess your immune response to COVID-19 infection or vaccination over a 5 year period. We are looking for children and adults aged 7-95 years, and plan to collect blood every 2-6 months over the study period. (Compensation provided for the first year).
The purpose of the EPPIK study is to gain further experience on the use of sparsentan in children.
We still have a lot to learn about why people develop glomerular disease and what the best medicines are to treat these diseases. Diabetes is a common, chronic illness and many people with glomerular disease also have diabetes. Currently, there is no information telling us the best ways to treat patients with both diabetes and glomerular disease, or how to counsel them about prognosis and risks for complications. This substudy of the Cure Glomerulopathy Network brings together information and laboratory specimens from patients with diabetes and glomerular disease to speed up and improve health research for their care.
The study tests the safety and efficacy of a new type of drug, administered by intravenous infusion, for the treatment of lupus nephritis or IgA Nephropathy. You might be on the drug or on the placebo (no active drug ) and will help to figure out if this new drug is a good alternative or complement to existing drugs.
The CureGN Network acts as a "library" of data for investigators across the world to use to help us ask the following questions: 1) What is the disease?; 2) Why did it happen to me?; 3) Can it be passed down to my family members?; 4) What treatments work the best with the least side effects?
Do you have multiple myeloma? Have you had a stem cell transplant? If so, you may be able to take part in a research study looking at the effectiveness of giving a drug called daratumumab, along with lenalidomide, after a stem cell transplant to patients with multiple myeloma.